|
|
||||||||

1 Laboratory of Clinical and Epidemiological Virology, Rega Institute for Medical Research, University of Leuven, Belgium
2 The James Graham Brown Cancer Center, University of Louisville, KY, USA
3 The Jackson Laboratory, Bar Harbor, ME, USA
Correspondence
Marc Van Ranst
marc.vanranst{at}uz.kuleuven.ac.be
| ABSTRACT |
|---|
|
|
|---|
Present address: Department of Microbiology and Immunology, Albert Einstein Cancer Center, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA. ![]()
The GenBank/EMBL/DDBJ accession number for the nucleotide sequence of the MmPV-1 genome is DQ269468.
GenBank accession numbers for all sequences used in this study are available in Supplementary Table S1 in JGV Online.
| INTRODUCTION |
|---|
|
|
|---|
Papillomatosis has been described in several species within the order Rodentia such as hamsters, guinea pigs, laboratory rats, mice, gerbils and American porcupines (Rector et al., 2005
; Sundberg, 1987
). The only rodent PVs that have been completely characterized at the genomic level were isolated from an African multimammate rat (Mastomys natalensis; MnPV), a Syrian golden hamster (Mesocricetus auratus; HaOPV) and a north-American porcupine (Erethizon dorsatum; EdPV-1) (Iwasaki et al., 1997
; Rector et al., 2005
; Tan et al., 1994
). Three papers report on the cloning and partial genetic characterization of the European harvest mouse (Micromys minutus) PV (O'Banion et al., 1988
; Sundberg et al., 1988
; Van Ranst et al., 1992b
) and partial sequence data of this MmPV were submitted to GenBank with accession nos AH002399
[GenBank]
and X65200
[GenBank]
.
In this study we report the complete genomic sequence of MmPV and its analysis. It contains 7393 bp and shows the seven classical PV open reading frames (ORFs) and non-coding region (NCR). Phylogenetic analysis places MmPV with HaOPV in the genus Pipapillomavirus (de Villiers et al., 2004
). The availability of the complete MmPV genome might provide researchers with an opportunity to study PV carcinogenesis in a homologous mouse model.
| METHODS |
|---|
|
|
|---|
Cloning and sequencing of the MmPV genome.
The cloning of the MmPV genome was described earlier (O'Banion et al., 1988
). Briefly, the phenol/chloroform-extracted DNA was digested with the single-cutting restriction enzyme EcoRI and cloned in a pUC18 vector. This vector was used to transform TB-1 cells. Hybridization with a bovine PV (BPV)-2 probe confirmed that a selected clone was papillomaviral-DNA positive. The first partial sequences were obtained with the M13 consensus primer set. Subsequent sequencing was performed using primer walking. Chromatogram sequencing files were inspected with Chromas 2.2 (Technelysium), and contigs were compiled using SeqMan II (DNASTAR).
DNA and protein sequence analysis.
The putative ORFs were predicted with the ORF Finder tool on the NCBI server of the National Institutes of Health (http://www.ncbi.nlm.nih.gov/gorf/gorf.html). The molecular mass of the putative proteins was calculated using the ExPASy Compute pI/Mw tool (http://www.expasy.org/tools/pi_tool.html). Multiple nucleotide sequence alignments were constructed in DAMBE version 4.2.7 (Xia & Xie, 2001
). The sequences of MmPV and 55 non-human animal and human PVs were first aligned at the amino acid level using CLUSTAL W (Thompson et al., 1994
). This alignment was then used as a template to align the nucleotide sequences. The alignment was corrected manually in GeneDoc version 2.6.002 (http://www.psc.edu/biomed/genedoc). The unambiguously alignable regions of the E1, E2, L2 and L1 ORFs were pasted together in one concatenated alignment which was used to construct a neighbour-joining phylogenetic tree in MEGA version 2.1 (Kumar et al., 2001
).
| RESULTS |
|---|
|
|
|---|
|
The E1 ORF encodes the largest MmPV protein (604 aa), which contains the conserved ATP-binding site for the ATP-dependent helicase (GPPDTGKS) in its carboxy-terminal part (Titolo et al., 1999
). Although a leucine-zipper domain is more commonly found in mucosal low risk HPVs, the E2 protein of MmPV contains a leucine-zipper domain (L-X6-L-X6-L-X6-L). We also identified a leucine-zipper domain in the E2 protein of the mucosal HaOPV, supporting the phylogenetic relationship between the two viruses. In HaOPV, the second leucine residue is replaced by a valine. Because both leucine and valine have hydrophobic side groups, this substitution should not pose any problems for the functionality of the leucine-zipper domain. Completely contained within the E2 gene, but read in another frame, we identified a putative E4 ORF with the typical high proline content (15 proline residues out of 121 aa). MmPV does not contain an identifiable E5 or E8 ORF.
The late region encodes the major (L1) and minor (L2) capsid protein genes. Both L1 and L2 contain a series of arginine and lysine residues at their carboxy-terminal end, which are likely to function as nuclear localization signals.
The classic NCR between the stop codon of L1 and the start codon of E6 contains 557 bp (nt 68463). The NCR contains several regulators of the papillomavirus replication; this NCR usually contains an E1 recognition site flanked by two E2-binding sites. This conformation allows for the binding of an E1/E2 complex in order to activate the origin of replication. An E1-binding site (E1BS, TGATTGTTGCCAACTAT) is present at nt 73287344. The E1BS is flanked by an E2-binding site (E2BS) at nt 72947305 (ACCG-N4-CGGT) and a putative modified E2-binding site (E2BS*) at nt 73737384 (GACG-N4-CGGT). Since the E2BS and the E2BS* are equidistant from the E1BS (22 and 28 bp, respectively), both sites are probably functionally important. Two more E2BS* are located at position 71427153 (AACG-N4-CGGT) and 72207231 (ACCT-N4-CGGT). At its 5' end, the NCR also contains a polyadenylation site (TATAAAA, nt 73892), upstream of a CA dinucleotide (nt 7357) and the G/T cluster, necessary for the processing of the L1 and L2 capsid mRNA transcript (Birnstiel et al., 1985
). In the 3' end, a TATA box of the E6 promoter is present at nt 68946908 (TGCTGCTATATATAT). The NCR also contains a tandem repeat of 14 bp (CTATGTACTGTGAA) separated by 11 bp (nt 69456983). The putative function of this repeat is unknown, but might play a role in replication.
Sequence similarity to other papillomaviruses
Table 1
shows the pairwise sequence similarity between MmPV and the other rodent PVs (HaOPV, EdPV-1 and MnPV), the benign cutaneous human papillomavirus (HPV)-1a, HPV-4 and HPV-5, representing the gamma- and betapapillomavirus genera, respectively, and the prototype high-risk mucosal HPV-16. Since a probe based on the BPV-2 genome was used to confirm the presence of PV DNA (O'Banion et al., 1988
), BPV-2 was also included (Table 1
). The L1 sequences of MmPV and HaOPV share 77.4 % sequence similarity at the nucleotide level. According to the recently published definitions, this places MmPV together with HaOPV in species 1 of the genus Pipapillomavirus (de Villiers et al., 2004
). Interestingly, the L1 ORF of MmPV and HPV-4 share 61 % nucleotide similarity. This prompted us to compare the L1 ORF of HaOPV, MmPVs closest relative (Fig. 2
), to that of HPV-4. Our analysis showed 62 and 63 % similarity at the nucleotide and amino acid level, respectively. This suggests that, according to our analysis, HaOPV and MmPV should be classified in species 6 of the genus Gammapapillomavirus. However, because MmPV and HaOPV infect rodents, while the members of the genus Gammapapillomavirus infect humans, we believe that the current classification into Pipapillomavirus and Gammapapillomavirus should be maintained.
|
|
| DISCUSSION |
|---|
|
|
|---|
Although the first prophylactic species- and type-specific (polyvalent) vaccines are used successfully to protect several non-human animals against PV infections (Lin et al., 1992
; Pilacinski et al., 1986
; Suzich et al., 1995
) and the commercialization of an HPV vaccine is being prepared (Shaw, 2005
), there is still a long road to travel before human and animal PV infections are eradicated (Franco & Harper, 2005
). A number of non-human animal models played a ground-breaking role in our understanding of papillomaviral disease (Campo, 2002
). Although animal models, such as the BPV, the cottontail rabbit PV, the canine PV and the rhesus monkey PV, have been used with promising results as homologous test systems (Campo, 2002
; Harvey et al., 1998
; Jahan-Parwar et al., 2003
; Peh et al., 2002
), the experimental use of these animals has its own specific problems (e.g. cost, technical support and ethical questions).
The development of a successful therapeutic vaccine against cervical cancer depends on understanding the pathogenesis of cervical cancer. This research has been hampered by the lack of an accessible animal model for PV infections. The difficulty in creating a good animal model lies in the species-specific nature of PVs. Rodents or other non-human mammals can therefore not be readily infected with an HPV type. This problem has been circumvented by using heterologous test systems. Most heterologous test systems use fast-growing transplantable tumours, e.g. the use of BPV-2 to induce cutaneous fibrosarcomas in hamsters (Moar et al., 1981
). The malignancies observed in human cervical cancer patients usually have a much slower progression, which might lead to immune suppression and/or immune tolerance. Heterologous test systems suffer the extra drawback of not using a host species specific own PV, which makes extrapolation to other animals (including humans) even harder. So far, no PVs have been isolated from inbred laboratory mice. The availability of a mouse model might prove essential to our understanding of PV pathogenesis. Not only are mice the most commonly used laboratory animals, but extensive research materials and immunological and molecular biological data related to mice are also available. With the availability of the complete genomic sequence of this wild mouse species PV, it should become possible for researchers to use this virus in a homologous test system, thus speeding up the development of both vaccines and antiviral drugs. Although MmPV causes cancer in its natural host, thus making it a good target for a model system, its natural host might prove to be a problem. Micromys minutus are wild rodents, which require special permission from the US Department of Agriculture (USDA) to be used in the laboratory in the US. Even with this special permission, these rodents will not breed outside their natural habitat. A transgenic mouse model which expresses the MmPV oncogenes in their epidermis should mimic what happens upon regular infection with MmPV, thus allowing us to exploit the well-studied mouse genetics and immunology to study the molecular pathways leading to squamous cell carcinoma.
| ACKNOWLEDGEMENTS |
|---|
| REFERENCES |
|---|
|
|
|---|
Campo, M. S. (2002). Animal models of papillomavirus pathogenesis. Virus Res 89, 249261.[CrossRef][Medline]
de Villiers, E. M., Fauquet, C., Broker, T. R., Bernard, H. U. & zur Hausen, H. (2004). Classification of papillomaviruses. Virology 324, 1727.[CrossRef][Medline]
Franco, E. L. & Harper, D. M. (2005). Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 23, 23882394.[CrossRef][Medline]
Hafner, M. S. & Nadler, S. A. (1988). Phylogenetic trees support the coevolution of parasites and their hosts. Nature 332, 258259.[CrossRef][Medline]
Harvey, S. B., Cladel, N. M., Budgeon, L. R., Welsh, P. A., Griffith, J. W., Lang, C. M. & Christensen, N. D. (1998). Rabbit genital tissue is susceptible to infection by rabbit oral papillomavirus: an animal model for a genital tissue-targeting papillomavirus. J Virol 72, 52395244.
Iwasaki, T., Maeda, H., Kameyama, Y., Moriyama, M., Kanai, S. & Kurata, T. (1997). Presence of a novel hamster oral papillomavirus in dysplastic lesions of hamster lingual mucosa induced by application of dimethylbenzanthracene and excisional wounding: molecular cloning and complete nucleotide sequence. J Gen Virol 78, 10871093.[Abstract]
Jahan-Parwar, B., Chhetri, D. K., Hart, S., Bhuta, S. & Berke, G. S. (2003). Development of a canine model for recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 112, 10111013.[Medline]
Jenson, A. B., Geyer, S., Sundberg, J. & Ghim, S. (2001). Human papillomavirus and skin cancer. J Investig Dermatol Symp Proc 6, 203206.[CrossRef][Medline]
Kumar, S., Tamura, K., Jakobsen, I. B. & Nei, M. (2001). MEGA2: molecular evolutionary genetics analysis software. Bioinformatics 17, 12441245.
Lin, Y. L., Borenstein, L. A., Selvakumar, R., Ahmed, R. & Wettstein, F. O. (1992). Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology 187, 612619.[CrossRef][Medline]
Moar, M. H., Campo, M. S., Laird, H. M. & Jarrett, W. F. (1981). Unintegrated viral DNA sequences in a hamster tumor induced by bovine papilloma virus. J Virol 39, 945949.
O'Banion, M. K., Reichmann, M. E. & Sundberg, J. P. (1988). Cloning and characterization of a papillomavirus associated with papillomas and carcinomas in the European harvest mouse (Micromys minutus). J Virol 62, 226233.
Peh, W. L., Middleton, K., Christensen, N., Nicholls, P., Egawa, K., Sotlar, K., Brandsma, J., Percival, A., Lewis, J. & other authors (2002). Life cycle heterogeneity in animal models of human papillomavirus-associated disease. J Virol 76, 1040110416.
Pilacinski, W. P., Glassman, D. L., Glassman, K. F., Reed, D. E., Lum, M. A., Marshall, R. F., Muscoplat, C. C. & Faras, A. J. (1986). Immunization against bovine papillomavirus infection. Ciba Found Symp 120, 136156.[Medline]
Rector, A., Bossart, G. D., Ghim, S. J., Sundberg, J. P., Jenson, A. B. & Van Ranst, M. (2004). Characterization of a novel close-to-root papillomavirus from a Florida manatee by using multiply primed rolling-circle amplification: Trichechus manatus latirostris papillomavirus type 1. J Virol 78, 1269812702.
Rector, A., Tachezy, R., Van Doorslaer, K., MacNamara, T., Burk, R. D., Sundberg, J. P. & Van Ranst, M. (2005). Isolation and cloning of a papillomavirus from a North American porcupine by using multiply primed rolling-circle amplification: the Erethizon dorsatum papillomavirus type 1. Virology 331, 449456.[CrossRef][Medline]
Shaw, A. R. (2005). Human papillomavirus vaccines in development: if they're successful in clinical trials, how will they be implemented?. Gynecol Oncol 99, S246S248.[CrossRef][Medline]
Steppan, S., Adkins, R. & Anderson, J. (2004). Phylogeny and divergence-date estimates of rapid radiations in muroid rodents based on multiple nuclear genes. Syst Biol 53, 533553.[CrossRef][Medline]
Sundberg, J. P. (1987). Papillomavirus infections in animals. In Papillomaviruses and Human Disease, pp. 40103. Edited by K. J. Syrjänen, L. Gissmann & L. G. Koss. Berlin: Springer-Verlag.
Sundberg, J. P., O'Banion, M. K., Shima, A., Knupp, C. & Reichmann, M. E. (1988). Papillomas and carcinomas associated with a papillomavirus in European harvest mice (Micromys minutus). Vet Pathol 25, 356361.[Abstract]
Sundberg, J. P., Van Ranst, M., Burk, R. D. & Jenson, A. B. (1997).The nonhuman (animal) papillomaviruses: host range, epitope conservation, and molecular diversity. In Human Papillomavirus Infections in Dermatovenereology, pp. 4768. Edited by G. von Krogh & G. Gross. Boca Raton, FL: CRC Press.
Suzich, J. A., Ghim, S. J., Palmer-Hill, F. J., White, W. I., Tamura, J. K., Bell, J. A., Newsome, J. A., Jenson, A. B. & Schlegel, R. (1995). Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A 92, 1155311557.
Tachezy, R., Duson, G., Rector, A., Jenson, A. B., Sundberg, J. P. & Van Ranst, M. (2002a). Cloning and genomic characterization of Felis domesticus papillomavirus type 1. Virology 301, 313321.[CrossRef][Medline]
Tachezy, R., Rector, A., Havelkova, M., Wollants, E., Fiten, P., Opdenakker, G., Jenson, B., Sundberg, J. & Van Ranst, M. (2002b). Avian papillomaviruses: the parrot Psittacus erithacus papillomavirus (PePV) genome has a unique organization of the early protein region and is phylogenetically related to the chaffinch papillomavirus. BMC Microbiol 2, 1927.[CrossRef][Medline]
Tan, C. H., Tachezy, R., Van Ranst, M., Chan, S. Y., Bernard, H. U. & Burk, R. D. (1994). The Mastomys natalensis papillomavirus: nucleotide sequence, genome organization, and phylogenetic relationship of a rodent papillomavirus involved in tumorigenesis of cutaneous epithelia. Virology 198, 534541.[CrossRef][Medline]
Terai, M., DeSalle, R. & Burk, R. D. (2002). Lack of canonical E6 and E7 open reading frames in bird papillomaviruses: Fringilla coelebs papillomavirus and Psittacus erithacus timneh papillomavirus. J Virol 76, 1002010023.
Thompson, J. D., Higgins, D. G. & Gibson, T. J. (1994). CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22, 46734680.
Titolo, S., Pelletier, A., Sauve, F., Brault, K., Wardrop, E., White, P. W., Amin, A., Cordingley, M. G. & Archambault, J. (1999). Role of the ATP-binding domain of the human papillomavirus type 11 E1 helicase in E2-dependent binding to the origin. J Virol 73, 52825293.
Van Doorslaer, K., Rector, A., Vos, P. & Van Ranst, M. (2006). Genetic characterization of the Capra hircus papillomavirus: a novel close-to-root artiodactyl papillomavirus. Virus Res 118, 164169.[CrossRef][Medline]
Van Ranst, M., Kaplan, J. B. & Burk, R. D. (1992a). Phylogenetic classification of human papillomaviruses: correlation with clinical manifestations. J Gen Virol 73, 26532660.
Van Ranst, M., Tachezy, R., Pruss, J. & Burk, R. D. (1992b). Primary structure of the E6 protein of Micromys minutus papillomavirus and Mastomys natalensis papillomavirus. Nucleic Acids Res 20, 2889
Van Ranst, M., Kaplan, J. B., Sundberg, J. P. & Burk, R. D. (1995). Molecular evolution of papillomaviruses. In Molecular Basis of Virus Evolution, pp. 455476. Edited by A. Gibbs, C. H. Calisher & F. García-Arenal. Cambridge: Cambridge University Press.
Xia, X. & Xie, Z. (2001). DAMBE: software package for data analysis in molecular biology and evolution. J Hered 92, 371373.
Received 2 October 2006;
accepted 20 December 2006.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |